Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke
@article{Diener2018NonvitaminKOA, title={Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke}, author={H. Diener and G. Ntaios and M. O'Donnell and J. Easton}, journal={Expert Opinion on Pharmacotherapy}, year={2018}, volume={19}, pages={1597 - 1602} }
ABSTRACT Introduction: In patients with atrial fibrillation (AF), oral anticoagulation with vitamin K antagonists (VKA) (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention with a 60–70% relative reduction in stroke risk compared with placebo. Mortality is reduced by 26%. VKA have a number of well-documented shortcomings which were overcome by non-vitamin-K oral anticoagulants (NOACs). Areas covered: Results of randomized trials for four NOACs (apixaban… Expand
Topics from this paper
8 Citations
Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation
- Medicine
- European heart journal supplements : journal of the European Society of Cardiology
- 2020
- 1
- PDF
Stroke prevention in atrial fibrillation : update with NOAC treatment and the impact of reversal
- 2018
- PDF
Anticoagulant Selection in Relation to SAMe-TT2R2 Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry.
- Medicine
- Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
- 2020
Expert Consensus Statement for the Management of Patients with Embolic Stroke of Undetermined Source and Patent Foramen Ovale: a clinical guide by the Working Group for Stroke of the Hellenic Society of Cardiology and the Hellenic Stroke Organization.
- Medicine
- Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
- 2020
Stroke: Insights into Thromboembolism Treatment and Prevention through the Decades.
- Medicine
- Thrombosis and haemostasis
- 2019
- 1
- PDF
Quality of life and depression 3 months after intracerebral hemorrhage
- Medicine
- Brain and behavior
- 2019
- 7
- PDF
References
SHOWING 1-10 OF 43 REFERENCES
Novel oral anticoagulants in secondary prevention of stroke.
- Medicine
- Best practice & research. Clinical haematology
- 2013
- 11
Apixaban versus warfarin in patients with atrial fibrillation.
- Medicine
- The New England journal of medicine
- 2011
- 4,610
- PDF
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
- Medicine
- American heart journal
- 2009
- 332
- PDF
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
- Medicine
- European heart journal
- 2017
- 77
- PDF
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.
- Medicine
- European heart journal
- 2016
- 57
- PDF
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
- Medicine
- American heart journal
- 2010
- 415
- PDF
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
- Medicine
- American heart journal
- 2010
- 439
- PDF
Apixaban in patients with atrial fibrillation.
- Medicine
- The New England journal of medicine
- 2011
- 1,545
- PDF
Dabigatran versus warfarin in patients with atrial fibrillation.
- Medicine
- The New England journal of medicine
- 2009
- 6,479
- PDF